FlucloxacillinDBL Flucloxacillin Sodium
Recommended Infectious diseaseUnrestrictedNot applicable line
Supply of flucloxacillin 1 g injection in a 10 vial pack to address ongoing shortage of the 5 vial pack size on the Australian market.
1
Submissions
2015–15
On the record
—
ICER range
Not modelled
Cost basis
Decision on record
- Meeting Nov 2015 Recommended Beta-lactam antibacterials
Access path
- TGA registered · DBL Flucloxacillin Sodium
TGA label equal than the PBS population
- Nov 2015Recommended
- PBS listing · Unrestricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
3.1 The PBAC recommended listing of the proposed alternative pack size of flucloxacillin 1 g injection to maintain supply on the PBS in light of an ongoing shortage of the 5 vial pack size in the Australian market.PSD · Nov 2015
3.2 The PBAC recommended that listing should be under same conditions as the currently available 5 vial pack size of flucloxacillin 1 g. Outcome: RecommendedPSD · Nov 2015
Cost-effectiveness
not-modelled — this is a minor submission for an alternative pack size, not a new formulation or clinical evaluation
Decision context
PopulationPatients requiring flucloxacillin 1 g injection (same indication as existing 5 vial pack size)
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2015 | Recommended | — | — | Cost-minimisation |
Similar precedents
Regulatory · TGA
Label equal than PBS population — PBAC recommendation covers same indication as TGA label—patients requiring flucloxacillin 1 g injection, differing only in pack size.